A double-blind, placebo controlled single centre trial to evaluate the dose-relationship of the effects of vaginally administered oxytocin on the vaginal mucosal membrane in postmenopausal women

Trial Profile

A double-blind, placebo controlled single centre trial to evaluate the dose-relationship of the effects of vaginally administered oxytocin on the vaginal mucosal membrane in postmenopausal women

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2013

At a glance

  • Drugs Oxytocin (Primary)
  • Indications Atrophic vaginitis
  • Focus Therapeutic Use
  • Sponsors Peptonic Medical
  • Most Recent Events

    • 21 Nov 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01987804 ).
    • 01 Sep 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 13 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top